Treatment of refractory prurigo nodularis with lenalidomide

Archives of Dermatology

Volumn 148, Issue 7, 2012, Pages 794-796

  Kanavy, Holly ^a   Bahner, Jennifer ^a   Korman, Neil J ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; ANTIHISTAMINIC AGENT; BUSPIRONE; CAPSAICIN; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; ETANERCEPT; GABAPENTIN; LENALIDOMIDE; MINOCYCLINE; NALTREXONE; PREDNISONE; PSORALEN; TACROLIMUS; THALIDOMIDE;

ADULT; AFRICAN AMERICAN; ARTICLE; ASTHMA; BEDTIME DOSAGE; BODY SURFACE; CASE REPORT; CONSTIPATION; CRYOTHERAPY; DEPRESSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERPIGMENTATION; HYPERTENSION; IMMUNOMODULATION; INSOMNIA; LICHENOID; MIGRAINE; MOOD DISORDER; MORNING DOSAGE; NEURODERMATITIS; PAPULE; PERIPHERAL NEUROPATHY; PHOTOTHERAPY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; SKIN NODULE; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TERATOGENICITY; THROMBOEMBOLISM; TOXIC EPIDERMAL NECROLYSIS; ULTRAVIOLET B RADIATION; WOUND HEALING;

FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MIDDLE AGED; PRURIGO; PRURITUS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84863911649     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.2918     Document Type: Article

References (22)

1. Wallengren J. Prurigo: diagnosis and management. Am J Clin Dermatol. 2004;5(2):85-95.
2. Rowland Payne CM, Wilkinson JD, McKee PH, Jurecka W, Black MM. Nodular prurigo - a clinicopathological study of 46 patients. Br J Dermatol. 1985;113(4):431-439.
3. Arck PC, Slominski A, Theoharides TC, Peters EM, Paus R. Neuroimmunology of stress: skin takes center stage. J Invest Dermatol. 2006;126(8):1697-1704.
4. Wong SS, Goh CL. Double-blind, right/left comparison of calcipotriol ointment and betamethasone ointment in the treatment of prurigo nodularis. Arch Dermatol. 2000;136(6):807-808.
5. Ständer S, Luger TA. Antipruritic effects of pimecrolimus and tacrolimus [in German]. Hautarzt. 2003;54(5):413-417.
6. Saraceno R, Nisticò SP, Capriotti E, de Felice C, Rhodes LE, Chimenti S. Monochromatic excimer light (308 nm) in the treatment of prurigo nodularis. Photodermatol Photoimmunol Photomed. 2008;24(1):43-45.
7. Siepmann D, Luger TA, Ständer S. Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series [in German]. J Dtsch Dermatol Ges. 2008;6(11):941-946.
8. Dereli T, Karaca N, Inanir I, Oztürk G. Gabapentin for the treatment of recalcitrant chronic prurigo nodularis. Eur J Dermatol. 2008;18(1):85-86.
9. Brune A, Metze D, Luger TA, Ständer S. Antipruritic therapy with the oral opioid receptor antagonist naltrexone: open, non-placebo controlled administration in 133 patients [in German]. Hautarzt. 2004;55(12):1130-1136.
10. Ständer S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol. 2001;44(3):471-478.
11. Doherty SD, Hsu S. A case series of 48 patients treated with thalidomide. J Drugs Dermatol. 2008;7(8):769-773.
12. Jøhnke H, Zachariae H. Thalidomide treatment of prurigo nodularis [in Danish]. Ugeskr Laeger. 1993;155(38):3028-3030.
13. Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J. 2005;7(1):E14-E19. http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC2751493/?tool=pubmed. Accessed March 31, 2012.
14. Grosshans E, Illy G. Thalidomide therapy for inflammatory dermatoses. Int J Dermatol. 1984;23(9):598-602.
15. Bastuji-Garin S, Ochonisky S, Bouche P, et al; Thalidomide Neuropathy Study Group. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol. 2002;119(5):1020-1026.
16. Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer. 2002;87(10):1166-1172.
17. Corral LG, Muller GW, Moreira AL, et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor α inhibitory activity. Mol Med. 1996;2(4):506-515.
18. Zeldis JB, Knight R, Hussein M, Chopra R, Muller G. A review of the history, properties, and use of the immunomodulatory compound lenalidomide. Ann N Y Acad Sci. 2011;1222:76-82.
19. Giagounidis A, Fenaux P, Mufti GJ, et al. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol. 2008;87(5):345-352.
20. Sviggum HP, Davis MD, Rajkumar SV, Dispenzieri A. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol. 2006;142(10):1298-1302.
21. Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009;23(11):2147-2152.
22. Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol. 2009;146(2):164-170.